SER Company Profile and Key Details

Serina Therapeutics, Inc. (AMEX:SER) closed at $2.23 USD, gaining $0.23 (11.50%) from the previous close of $2.00. The stock is currently mid-range between its 52-week high and low $1.22 and $7.92. With a market capitalization of about $24.16 million, Serina Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.03). Key stats such as the average daily volume over the past year has been around 101.86 thousand shares, volume is running light vs its 52-week average. Headquartered in Huntsville, AL, Serina Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven A. Ledger, the company employs approximately 16 people and listed since January 21, 2000. Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain.

SER has shown mixed momentum, gaining 16.19% over the past week and -40.31% over the past quarter, though year-to-date performance is up 50.03%. Short-term trend indicators are bullishly aligned (SMA20 -16.18%, SMA50 -25.13%, SMA200 -59.25%). The stock’s 14-day RSI is 40.43 (neutral), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -77.15% below its high and over 17.98% above its low. Average 10-day trading volume of 55.82 thousand shares is below the 3-month average of 104.57 thousand, indicating normal recent market interest.

Serina Therapeutics, Inc. trades at a P/E ratio of -1.07, slightly below the S&P 500 average, with a price-to-sales ratio of 175.83 and a price-to-book ratio of 1.44 suggesting the stock is closer to book value. The P/FCF stands at -1.25, also above market averages.